Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 3:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Low Dose Corticosteroids Clear all
Completed Phase 3 Interventional Results available

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
prasterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
280
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 29, 2026, 3:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes

NCT00591006
View directory record Official record
Conditions
Healthy
Interventions
Phenytoin (brand name Dilantin), Hydrocortisone, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Sep 29, 2026, 3:29 AM EDT
Completed Phase 2 Interventional Results available

BI 671800 in Asthmatic Patients on Inhaled Corticosteroids

NCT01103349
View directory record Official record
Conditions
Asthma
Interventions
BI 671800, Placebo, Montelukast
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • Plymouth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Sep 29, 2026, 3:29 AM EDT
Terminated Early Phase 1 Interventional Results available

Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus

NCT01313923
View directory record Official record
Conditions
Pemphigus
Interventions
Sirolimus (formerly known as Rapamycin)
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 29, 2026, 3:29 AM EDT
Terminated Phase 1 Interventional

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

NCT05276492
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic
Interventions
Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log, Low-fat meal
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 29, 2026, 3:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

NCT00251004
View directory record Official record
Conditions
Kidney Transplantation, Graft Rejection
Interventions
Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA), Basiliximab, Corticosteroids
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Sep 29, 2026, 3:29 AM EDT
Completed Early Phase 1 Interventional

Effects of Glucocorticoids on Cognition in HIV-infected Women

NCT03237689
View directory record Official record
Conditions
Hiv
Interventions
Hydrocortisone, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 29, 2026, 3:29 AM EDT
Withdrawn Phase 2 Interventional

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

NCT00514982
View directory record Official record
Conditions
Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
Interventions
Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 29, 2026, 3:29 AM EDT
Withdrawn Phase 2 Interventional

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

NCT02763761
View directory record Official record
Conditions
Renal Cell Carcinoma, Melanoma, Lung Cancer
Interventions
Infliximab + Prednisone, Methylprednisolone + Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 29, 2026, 3:29 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

NCT04293562
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 29, 2026, 3:29 AM EDT
Completed Phase 4 Interventional Results available

Inpatient Diabetes on Corticosteroids

NCT01970241
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
NPH, Correction Factor
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 29, 2026, 3:29 AM EDT
Terminated Phase 4 Interventional Results available

Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease

NCT01554488
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea
Interventions
Inhaled Fluticasone Propionate
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 29, 2026, 3:29 AM EDT
Completed Phase 1Phase 2 Interventional

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

NCT02649790
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
Interventions
KPT-8602, ASTX727, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
26
States / cities
Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 29, 2026, 3:29 AM EDT
Terminated Phase 2 Interventional Results available

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

NCT01396278
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Fluticasone propionate, BI 54903
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
37
States / cities
Fountain Valley, California • Fullerton, California • Long Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 29, 2026, 3:29 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance

NCT07494084
View directory record Official record
Conditions
Shift Work Schedule, Circadian Rhythm, Insulin Resistance, Circadian Misalignment
Interventions
Metyrapone And Hydrocortisone, Dextrose, insulin
Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 29, 2026, 3:29 AM EDT
Completed Phase 4 Interventional Results available

Belatacept 3 Month Post Transplant Conversion Study

NCT02213068
View directory record Official record
Conditions
Transplant; Failure, Kidney, EBV
Interventions
belatacept, Tacrolimus, MPA
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 29, 2026, 3:29 AM EDT
Completed Phase 4 Interventional Results available

Effect of Low Dose Corticosteroids on Perioperative Markers of Thrombosis and Fibrinolysis in Total Knee Arthroplasty

NCT01815918
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Hydrocortisone, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 29, 2026, 3:29 AM EDT
Terminated Phase 4 Interventional

Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation

NCT00656266
View directory record Official record
Conditions
End-stage Liver Disease, Renal Insufficiency, Renal Failure
Interventions
mycophenolate mofetil, placebo medication
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 16 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 29, 2026, 3:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy

NCT00733096
View directory record Official record
Conditions
Lumbosacral Radiculopathy
Interventions
etanercept, methylprednisolone, normal saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2012 · Synced Sep 29, 2026, 3:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

NCT00622869
View directory record Official record
Conditions
Liver Transplantation
Interventions
Tacrolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Everolimus (reduced tacrolimus), Everolimus (tacrolimus elimination), Corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 29, 2026, 3:29 AM EDT
Recruiting No phase listed Observational

QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol

NCT07787117
View directory record Official record
Conditions
Asthma
Interventions
None (observational study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 29, 2026, 3:29 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma

NCT01248065
View directory record Official record
Conditions
Asthma
Interventions
Vitamin D3, Ciclesonide
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Sep 29, 2026, 3:29 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age

NCT01156792
View directory record Official record
Conditions
Asthma
Interventions
FP 100, GSK2190915 100, GSK2190915 300, montelukast, placebo, FP/SAL 100/50
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older · Female only
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
32
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 29, 2026, 3:29 AM EDT
Recruiting No phase listed Observational

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

NCT00576069
View directory record Official record
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 29, 2026, 3:29 AM EDT